Skip to main content

Non-anaemic Patients Undergoing Cardiac Surgery

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pharmacosmos
PharmacosmosDenmark - Holbaek
1 program
1
Iron isomaltoside 1000Phase 31 trial
Active Trials
NCT01563367Completed74Est. Sep 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PharmacosmosIron isomaltoside 1000

Clinical Trials (1)

Total enrollment: 74 patients across 1 trials

NCT01563367PharmacosmosIron isomaltoside 1000

A Prospective, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Non-Anaemic Patients Undergoing Elective or Sub-Acute Coronary Artery Bypass Graft, Valve Replacement or a Combination Thereof

Start: Jan 2012Est. completion: Sep 201374 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.